Please login to the form below

Not currently logged in
Email:
Password:

Lilly appoints Maura Dickler as VP of late phase oncology development

She will join the pharma firm from the Memorial Sloan Kettering Cancer Center

Maura Dickler is set to join Lilly Oncology as VP of late phase development on May 7.

She will move to the pharmaceutical company from the prestigious Memorial Sloan Kettering Cancer Center, where she currently serves as associate member, Breast Medicine Service within its Department of Medicine.

In her new role at Lilly Oncology she will report to senior vice president, global development and medical affairs Levi Garraway.

He said: "Dr Dickler is an internationally recognized oncology leader with drug development expertise spanning a wide range of therapeutic modalities. Moreover, she is an exceptionally gifted clinician for whom patients are at the center of everything she does. We are thrilled to have Dr. Dickler join us at Lilly."

In addition to her role at Sloan Kettering, Dr Dickler concurrently serves as associate professor of medicine at New York’s Weill Cornell Medical College.

15th March 2018

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...

Infographics